---
title: "NCQA partners with Komodo to use Healthcare Map and AI for HEDIS measure development"
id: "news-news-fierce-healthcare-c66b85b54ef8d0d51713f3f4"
canonical_url: "https://medichelpline.com/news/news-news-fierce-healthcare-c66b85b54ef8d0d51713f3f4"
content_type: "medical_news_article"
category: "Industry"
source_name: "Fierce Healthcare"
source_url: "https://www.fiercehealthcare.com/health-tech/ncqa-use-komodo-platform-future-development-hedis-measures"
published_at: "2026-08-28T20:19:15.507Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# NCQA partners with Komodo to use Healthcare Map and AI for HEDIS measure development
## Metadata & Source Attribution
- **Canonical URL:** https://medichelpline.com/news/news-news-fierce-healthcare-c66b85b54ef8d0d51713f3f4
- **Category:** [Industry](https://medichelpline.com/news/industry.md)
- **Reporting Source:** Fierce Healthcare
- **Original Source URL:** [Read Original Article](https://www.fiercehealthcare.com/health-tech/ncqa-use-komodo-platform-future-development-hedis-measures)
- **Published At:** 2026-08-28T20:19:15.507Z
## Executive Summary & Key Highlights
- The National Committee for Quality Assurance (NCQA) has entered a multi-year strategic partnership with Komodo Health to modernize development of **HEDIS** quality measures. - NCQA researchers will gain access to Komodo’s **Healthcare Map**, which comprises over **330 million de-identified patient journeys**, enabling analysis across insurance types, care settings and populations from a single longitudinal data source. - The agreement also provides NCQA with Komodo’s **Marmot**, an AI-powered healthcare intelligence platform designed to produce transparent, reproducible outputs for complex analytic questions. - Komodo previously supported NCQA testing of the Follow-Up After Positive Colorectal Cancer Non-Invasive Screening Test (COF-E) for Measurement Year 2027; testing time for Medicare Advantage, Medicaid and commercial populations fell to about a month and was reported as nearly halved. - NCQA will remain solely responsible for developing HEDIS measures; the partnership aims to speed evaluation of new measures and ensure they reflect **real-world evidence** drawn from multiple insurance populations. - Komodo says the Healthcare Map is continuously refined to expand its breadth, depth and longitudinal coverage; NCQA plans to leverage the platform broadly for measure innovation, maintenance and evaluation.
## In-Depth Reporting & Editorial Analysis
## NCQA and Komodo form multi-year partnership to modernize HEDIS measure development The National Committee for Quality Assurance (NCQA) has struck a multi-year strategic partnership with Komodo Health to change how healthcare quality measures are developed and tested. Under the agreement, NCQA researchers will use Komodo’s **Healthcare Map**—a longitudinal dataset of more than **330 million de-identified patient journeys**—and Komodo’s AI platform, **Marmot**, to analyze care across insurance types, care settings and patient populations from a single source. NCQA remains the sole authority responsible for creating **HEDIS** (Healthcare Effectiveness Data and Information Set) measures, but the new data and analytic access is intended to make measure evaluation faster and more aligned with real-world patterns of care. ## What the partnership provides: data and AI tools Komodo’s Healthcare Map aggregates claims, lab and other de-identified data into a single longitudinal view covering Medicare, Medicaid and commercial populations. According to Komodo, the Map is continuously refined to increase its breadth, depth and longitudinal coverage. NCQA will also have access to Marmot, Komodo’s AI-powered healthcare intelligence platform, which is designed to help researchers explore complex questions and produce transparent, reproducible outputs. Tricia Elliott, NCQA’s vice president of quality implementation, told Fierce Healthcare that using the Healthcare Map "has greatly streamlined" testing workflows. Because the Map includes multiple insurance populations in one dataset, NCQA researchers can evaluate measures across insurance types without running separate analyses for each population. ## Early use case: colorectal cancer follow-up measure Komodo supported NCQA’s development and testing of a new measure—Follow-Up After Positive Colorectal Cancer Non-Invasive Screening Test, referred to as COF-E—that is slated for implementation in Measurement Year 2027. For that project, NCQA used lab data and claims information to assess follow-up rates after a positive stool-based screening test. NCQA reported that testing time was cut nearly in half when using Komodo’s resources, taking about a month to evaluate Medicare Advantage, Medicaid and commercial populations. The shortened testing timeline demonstrates the operational efficiencies NCQA expects to gain from the partnership. ## Why NCQA says this matters for measure development Quality measures guide how healthcare organizations assess performance and identify opportunities to improve care. NCQA leaders said a comprehensive, current view of care across patient populations is critical for creating measures that reflect what is actually happening in practice. Komodo co-founder and co-CEO Web Sun told Fierce Healthcare that the Healthcare Map and Marmot were engineered to provide that kind of comprehensive view. NCQA’s stated objective is to leverage Komodo’s capabilities broadly to support ongoing measure innovation, maintenance and evaluation, while continuing to tailor specific testing approaches to individual project needs. ## How this differs from traditional measure testing Historically, developing and testing new quality measures required pulling together disparate datasets and conducting field testing with individual payers or partners. That process often required separate analyses for each population studied and could take two to three months for testing alone. By contrast, NCQA said the single-source approach with Komodo reduced duplication of effort and allowed more rapid cross-population comparisons. This single-dataset workflow aims to accelerate evaluation timelines and deliver measure testing that is more consistently comparable across insurance types. ## Data stewardship and scope The source article notes that the Healthcare Map is composed of de-identified patient journeys and that Komodo continuously refines and expands the dataset. Specific technical details about de-identification processes, data sources beyond lab and claims, or privacy safeguards were not reported in the source. NCQA retains responsibility for the design and validation decisions for HEDIS measures; Komodo’s role is to provide data and analytic tooling to support those activities. ## What’s next for HEDIS testing and real-world evidence NCQA indicated it expects Komodo to serve as a key platform supporting HEDIS measure testing activities across NCQA’s portfolio. The organization plans to use the capability broadly for measure innovation, maintenance and evaluation, while allowing individual project needs to guide specific testing approaches. Komodo said it is focused not only on expanding its dataset but also on helping organizations turn that data into actionable intelligence for decision-making. The source did not provide a detailed roadmap for which HEDIS measures will be next or timelines beyond the Measurement Year 2027 COF-E implementation. ## Bottom line The NCQA–Komodo partnership links a national quality oversight body with an AI-enabled, longitudinal healthcare dataset and analytics platform. NCQA aims to use these resources to shorten testing timelines, evaluate measures across multiple insurance populations from a single source, and align future **HEDIS** measures with patterns observed in real-world care. Specific future measures and detailed technical or privacy controls were not detailed in the report.
## Navigation
- [← Back to Industry News](https://medichelpline.com/news/industry.md)
- [← All Medical News Categories](https://medichelpline.com/news.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.